Introduction Observational studies using case-control designs have showed an increased
risk of pneumonia associated with inhaled corticosteroid (ICS)-containing medications in …

Background Use of inhaled corticosteroids (ICS) increases the risk of pneumonia in chronic
obstructive pulmonary disease (COPD), but the magnitude of risk with different ICS remains …

Introduction: Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease. To estimate the association between …

Background The use of inhaled corticosteroids in patients with chronic obstructive
pulmonary disease (COPD) has been associated with an increased risk of pneumonia in …

Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …

Background The use of inhaled corticosteroids (ICS) in combination with bronchodilators in
patients with COPD has been shown to decrease the rate of disease exacerbations and to …

Context Recent studies of inhaled corticosteroid (ICS) therapy for managing stable chronic
obstructive pulmonary disease (COPD) have yielded conflicting results regarding survival …

Clinicians should consider the long-term risks of pneumonia with the use of inhaled
corticosteroids in patients with COPD. Adequately powered long-term head-to-head trials …

Inhaled corticosteroid (ICS) use in chronic obstructive pulmonary disease (COPD) patients is
associated with a reduction of exacerbations and a potential risk of pneumonia. The …

Background Inhaled corticosteroids (ICS) are a prevailing treatment option for COPD
patients but recent guidelines have relegated their use predominantly to patients with …